After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NYSE-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. The current market capitalization of Takeda Pharmaceutical Co ADR is $46.50B. A total of 1.84 million shares were traded on the day, compared to an average of 1.87M shares.
In the most recent transaction, TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares of TAK for 8.10 per share on Jan 24. After the transaction, the 10% Owner now owns 3,755,583 company shares.
Dividend
The income generated by dividends is an indication that a company is improving its financial position, which is why investors prefer companies paying dividends. Takeda Pharmaceutical Co ADR pays an annual dividend of $0.63, resulting in a dividend yield of 4.24%, and it has a price to earnings (P/E) ratio of 37.06.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for TAK in the last 3 months, the mean price target is $15.79 with high estimates of $19.56 and low estimates of $13.71. In terms of 52-week highs and lows, TAK has a high of $17.15 and a low of $13.19.
As of this writing, TAK has an earnings estimate of $Northern Dynasty Minerals, Ltd. per share for the current quarter. EPS was calculated based on a consensus of Take-Two Interactive Software, estimates, with a high estimate of $TACK per share and a lower estimate of $TAL Education Group.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. TAK’s latest balance sheet shows that the firm has $875.00B in Cash & Short Term Investments as of fiscal 2022. There were $4.35T in debt and $2.15T in liabilities at the time. Its Book Value Per Share was $15.24, while its Total Shareholder’s Equity was $5.68T.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TAK is Buy with a score of 4.50.
